MedTrace Logo

Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer

NCT03691012 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2023-05-09

No results posted yet for this study

Summary

To demonstrate that detectable ctDNA in peripheral blood following debulking of the primary tumour or following completion of adjuvant treatment for is associated with subsequent disease recurrence in stage I-IV epithelial, fallopian tube and primary peritoneal cancer (Ovarian Cancer)

Conditions

Interventions

DIAGNOSTIC_TEST

Circulating tumour DNA testing

Circulating tumour DNA testing

Sponsors & Collaborators

Principal Investigators

  • Sumitra Ananda, Associate Professor · Walter and ELiza Hall Institute

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-09
Primary Completion
2020-12-31
Completion
2025-05-09

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03691012 on ClinicalTrials.gov